Cancer Solutions for Genetic Analysis
MassARRAY System– highly accurate, sensitive analysis for Cancer Research
Sequenom offers a broad portfolio of solutions for cancer research from DNA methylation and gene expression, to low frequency mutation and copy number analysis. At the heart is the MassARRAY® system, based on MALDI-TOF mass spectrometry. It enables highly accurate, sensitive, and high-throughput methods pivotal to cancer research.
Applications for Cancer Research
Genotyping & Copy Number
Somatic mutation profiling
DNA Methylation
Gene Expression
Product Spotlight for Cancer Mutation Profiling
Sequenom now offers the OncoCarta™ Panel v1.0, the most comprehensive multi-gene panel available for profiling rare somatic mutations. It enables you to rapidly profile genetic changes associated with tumor initation and progression.
- Comprehensive–the only panel for somatic mutation analysis with 19 oncogenes and 238 mutations
- Ready-to-go–Pre-designed assays you can run in your lab today
- High sensitivity– detect as low as 10% mutation frequency
- Small input DNA– less than 500 nanograms per sample, important when using FFPE tissue
For more information, view our OncoCarta™ Webinar
Customer Seminar Showcase– View: “Supporting Personalized Cancer Medicine with the MassARRAY System”
Select Testimonials from Cancer Researchers
"We conclude that MassEXTEND LOH analysis is a sensitive, high-throughput, and cost-effective method to screen SNP loci for LOH in formalin-fixed-paraffin-embedded tissue."
"This approach (MassARRAY) is more sensitive than conventional Sanger sequencing, having the potential to detect mutations that are present in only a subset of tumor cells or tumors with a high level of normal cell contamination, which is commonly the case in breast cancer."
Recent Publications in the News
Search our Publication database by cancer disease, gene, or author to access the latest peer-reviewed publications using the MassARRAY® system for cancer research.
Upcoming Events
View the roadshows, tradeshows, and other events where we will be highlighting our solutions for cancer research.
|